Astrazeneca (AZN) Price to Earnings (2009 - 2026)

Astrazeneca has reported Price to Earnings for 18 years, with the latest figure at 117.24 in Q2 2026.

• On a quarterly basis, Price to Earnings rose 32.59% year-over-year to 117.24 in Q2 2026; TTM through Jun 2026 was 28.14, a 7.74% increase from a year earlier, with the FY2025 full-year figure at 52.98, down 36.54% from the prior year.
• Price to Earnings was 117.24 for Q2 2026 at Astrazeneca, up from 99.25 in the prior quarter.
• The five-year high for Price to Earnings was 568.72 in Q2 2022, with the low at 78.14 in Q1 2025.
• Average Price to Earnings over 5 years is 176.35, with a median of 122.2 recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Price to Earnings soared 537.22% in 2022, then plunged 78.57% in 2023.
• Over 5 years, Price to Earnings stood at 232.97 in 2022, then dropped by 6.71% to 217.34 in 2023, then plunged by 37.7% to 135.41 in 2024, then dropped by 9.52% to 122.52 in 2025, then slipped by 4.31% to 117.24 in 2026.
• The last three Price to Earnings figures came in at 117.24 (Q2 2026), 99.25 (Q1 2026), and 122.52 (Q4 2025), per Business Quant data.